You are here

Smallpox

Vaccination News Home Page

http://www.idsociety.org/bt/biotemplate.cfm?template=sm_summary.htm

          

Bioterrorism 
Information & Resources

The bioterrorism section of the website is a collaboration between IDSA and the 
Center for Infectious Disease Research and Policy
at the University of Minnesota with
funding from the Centers for Disease Control and Prevention (CDC) and Pharmacia


Smallpox
Last updated: October 1, 2002
 

Agent
Pathogenesis
Epidemiology
Occurrence of Smallpox in the Pre-eradication Era
Global Eradication of Smallpox
Reservoir/Modes of Transmission/Communicability
Use of Smallpox as a Biological Weapon
Clinical Features of Variola Major
Ordinary Smallpox
Flat-Type (Malignant) Smallpox
Hemorrhagic Smallpox
Smallpox in Children
Clinical Features of Variola Minor
Differential Diagnosis
Differential Diagnosis of the Rash Illness
Distinguishing Features Between Smallpox and Chickenpox
Monkeypox
Diagnostic Issues
Criteria for Determining the Likelihood of Smallpox
Specimen Collection and Handling
Laboratory Diagnosis
Laboratory Response Network (LRN)
Tests for Detection and Identification of Variola Virus
Rapid Tests for Diagnosis of VZV and HSV
Testing in Areas With Confirmed Smallpox
Inadvertent Discovery of Variola Virus in a Laboratory Specimen
Treatment
Smallpox Vaccination
Historical Perspective
Dryvax Vaccinia Vaccine
New Vaccinia Vaccines
Recommendations for Use of Vaccinia Vaccines
Vaccination Schedule
Dosage and Route of Administration
Local Reaction to Vaccination
Contraindications and Precautions
Adverse Reactions
Treatment of Adverse Reactions with Vaccinia Immune Globulin
Use of Vaccine for Postexposure Prophylaxis
Use of Vaccine During a Smallpox Emergency
Infection Control
Public Health Reporting and Case Definitions
References

Agent

Variola virus classification:

  • DNA virus
  • Family Poxviridae, subfamily Chordopoxviridae, genus Orthopoxvirus

Virion morphology:

  • Brick-shaped virion approximately 200 nm in diameter (approximately the size of a bacterial spore)
  • Enveloped
  • Dumbell-shaped core containing nucleic acid and surrounded by a series of membranes
  • Replicates in the cytoplasm of host cells, forming B-type inclusion bodies (Guarnieri bodies), unlike varicella or herpes viruses, which replicate in the nucleus

Genetic composition:

  • The genome is composed of a single, linear, double-stranded DNA covalently closed at each end.
  • Average genome has 200,000 base pairs (200 kbp) and is among the largest animal viruses.
  • The genome includes genes that encode for viral DNA-dependent RNA polymerase and thymidine kinase
  • Genome has low G+C content (36% to 37%).
  • The genome of several strains has been completely sequenced and efforts are under way to assess the genetic diversity of existing variola viruses and to differentiate them (see References: National Center for Biotechnology Information; LeDuc 2001).
  • Extensive cross-neutralization between orthopoxviruses exists; therefore, neutralization tests are not useful in distinguishing variola virus from other orthopoxviruses (this feature also accounts for the protection against smallpox afforded by vaccination with cowpox and vaccinia viruses).

Variola viruses traditionally have been classified as variola major and variola minor on the basis of the severity of clinical illness caused by infection. Recognized variola minor strains include:

  • Alastrim
  • Amass
  • Kaffir

There are many viruses in the family Poxviridae with vertebrate host ranges that do not include humans; related viruses that can cause natural infections in humans include:

  • Other Orthopoxvirus species
    • Monkeypox virus
    • Vaccinia virus
    • Cowpox virus
  • Other Chordopoxviridae genera
    • Yatapoxviruses: tanapox virus, Yaba monkey tumor virus, and Yaba-like disease virus of monkeys
    • Parapoxviruses: Orf virus
    • Molluscipoxvirus: agent of molluscum contagiosum

Environmental survival of variola virus:

  • Inversely proportional to temperature and humidity (in the pre-eradication era, smallpox had a higher incidence in the winter and spring in those climates where these seasons had low temperature and humidity)

Back to top

Pathogenesis

The pathogenesis of smallpox involves the following steps (see References: Fenner 1988: Chapter 3; Henderson: Smallpox as a biological weapon):

  • The portal of entry for variola virus is usually through the oropharyngeal or respiratory mucosa; variola virus also can enter through the skin, and rarely, through the conjunctiva or placenta (see References: Fenner 1988: Chapters 1 and 3).
  • The virus migrates rapidly to regional lymph nodes.
  • Asymptomatic viremia occurs on the 3rd or 4th day after infection, with further dissemination of the virus to spleen, bone marrow, and other lymph nodes.
  • Secondary viremia occurs by the 8th to 12th day after initial infection; this is followed by onset of fever and toxemia.
  • The virus localizes in small blood vessels of the dermis and oropharyngeal mucosa, leading to initial onset of the enanthem and exanthem, at which point (about day 14) the patient becomes infectious. The spleen, lymph nodes, kidneys, liver, bone marrow, and other viscera also may contain large amounts of virus (see References: Breman 2002).
  • The development and evolution of skin lesions is an extremely valuable clue to the diagnosis and involves the following steps:
    • Dilatation of the capillaries in the papillary layer of the dermis occurs initially, followed by swelling of the endothelial cells in the vessel walls. Perivascular cuffing with lymphocytes, plasma cells, and macrophages can be seen.
    • Lesions then develop in the epidermis, where the cells become swollen and vacuolated; characteristic B-type inclusion bodies can be found in the cytoplasm.
    • The cells increase in size and the cell membranes rupture, leading to vesicular lesions.
    • Pustulation results from the migration of polymorphonuclear cells into the vesicle.
    • The contents of the pustule gradually become desiccated, leading to crusting or scabbing of the lesions.
    • Re-epithilialization and scarring occur as the lesions heal.
  • Death most commonly results from overwhelming toxemia, probably associated with circulating immune complexes.

Back to top

Epidemiology

Occurrence of Smallpox in the Pre-eradication Era

  • Smallpox likely originated in Egypt or India over 3,000 years ago (see References: WHO: Fact sheet on smallpox). Egyptian mummies dating from as early as 1500 BC showed characteristic pox-like skin lesions suggestive of smallpox.
  • Smallpox initially was introduced to the native populations of the Western Hemisphere by explorers from Europe and later by African slaves. The first recorded epidemic of smallpox in the New World occurred in 1507 on the island of Hispaniola (see References: Fenner 1988: Chapter 5). Eventually the disease spread throughout the hemisphere with devastating consequences for many native tribes.
  • By the mid-1700s, smallpox was a major endemic disease throughout the world, except in Australia, where it was first introduced in 1789 and again in 1829.
  • Following the famous observations of Edward Jenner at the end of the 18th century, vaccination against smallpox using cowpox virus became a widespread practice in Europe and the United States. During the 19th century, cowpox virus was gradually replaced by vaccinia virus as the agent used in vaccination (see Smallpox Vaccination: Historical Perspective). During the first half of the 20th century, smallpox vaccination using vaccinia virus was widespread, particularly in Europe and the United States.
  • By the early 1950s, endemic smallpox had been eradicated from Europe, the USSR, and North and Central America (see References: Fenner 1988: Chapter 5). However, the disease remained endemic throughout most of the developing world, with an estimated 50 million cases occurring each year (see References: WHO: Fact sheet on smallpox).

Global Eradication of Smallpox

  • In 1959, the 12th World Health Assembly of the World Health Organization (WHO) passed the first resolution for global eradication of smallpox; however, it was not until 1967 that substantial resources were dedicated to the project.
  • The basic strategy of smallpox eradication included: (1) mass smallpox vaccination campaigns and (2) surveillance and containment of outbreaks.
  • After an extensive, sustained, international collaboration over a 12-year period, the International Commission for the Global Certification of Smallpox Eradication declared in December 1979 that smallpox had been globally eradicated (see References: Fenner 1988: Chapter 27).
  • The last reported case of endemic smallpox occurred in Somalia in 1977, and the last case human case, which involved accidental laboratory exposure, occurred in Birmingham, England, in 1978 (see References: CDC: Laboratory associated smallpox-England; CDC: Smallpox surveillance-worldwide).
  • The following epidemiologic features of smallpox facilitated global eradication (see References: Fenner 1988: Chapter 4):
    • Humans are the only natural reservoir for variola virus.
    • Vectorborne transmission of the virus does not occur.
    • The virus does not survive in nature for prolonged periods of time.
    • The full-blown clinical illness is easily recognizable, allowing for accurate clinical surveillance of the disease.
    • The infectivity of variola virus is relatively low (ie, transmission generally requires relatively close face-to-face contact except in uncommon circumstances), making it possible to effectively interrupt chains of transmission.
    • Generally, only persons who develop the characteristic rash illness transmit the virus; subclinical illness is rare and transmission from subclinical cases is not of epidemiologic importance.
    • No chronic carrier state of the virus occurs.
    • An effective vaccine exists.
    • The incubation period (ie, 10 to 12 days) is long enough for a vaccination/containment strategy to be effective.

Reservoir/Modes of Transmission/Communicability

Reservoir
  • Before global eradication, the only reservoir for variola virus was humans. No natural reservoir for the virus currently exists.
  • Stocks of variola virus have been retained in two WHO-approved collaborating centers: the Centers for Disease Control and Prevention (CDC) in Atlanta and the Russian State Centre for Research on Virology and Biotechnology, Koltsovo, Novosibirsk Region, Russian Federation) (see References: WHO 2001).
  • There are concerns that not all the smallpox preparations developed in the Russian bioweapons program can be accounted for and that unknown caches of variola virus may exist (see References: Henderson 1998).
Modes of Transmission
  • Variola virus is predominantly transmitted person-to-person via inhalation of droplet nuclei (see References: Fenner 1988: Chapter 4). Transmission occurs most commonly among those with close face-to-face contact with an infected patient (particularly household contacts, since patients are usually ill enough to be confined to bed during the period of infectiousness).
  • Airborne transmission has been documented in two outbreaks that occurred in hospitals in the Federal Republic of Germany (one in 1961 and one in 1970) (see References: Wehrle 1970).
    • In the first outbreak, the index patient transmitted the virus to 19 persons, 10 of whom had no direct contact with the patient. The index patient had severe confluent skin involvement, ulcerative pharyngitis, and a barking cough.
    • In the second outbreak, the index patient transmitted the virus to 17 persons, none of whom had direct contact with the patient. The index patient had severe confluent skin lesions, severe bronchitis, and cough. Investigators noted that the relative humidity in the hospital was low (which may have facilitated survival of the virus) and that the design of the hospital set up strong air currents throughout the building (which may have facilitated dissemination of viral particles).
  • Fomite transmission (eg, from laundry and bedding) has been reported (see References: Dixon 1962). Contaminated fomites (ie, blankets) were used for intentional transmission of smallpox during the French-Indian wars in the United States in the 1700s (see References: Stearn 1945).
Communicability
  • The infectious dose is presumed to be low (10 to 100 organisms) (see References: Franz 1997).
  • Most epidemiologic data suggested that infectiousness in smallpox correlated with rash onset, with patients in the prodromal phase generally not considered infectious (see References: Henderson: Smallpox as a biological weapon). This is distinct from varicella infection (ie, chickenpox), in which patients are infectious before rash onset. However, patients with smallpox should be considered infectious from the time of onset of fever, because virus is present in, and shed from, the oral lesions as they ulcerate during the 1 to 2 days of fever preceding rash onset (see References: CDC: Interim smallpox response plan and guidelines: Guide A; Breman 2002).
  • Infectiousness is considered to be highest during the first week after rash onset when lesions in the mouth ulcerate and release large amounts of virus into the saliva.
  • The observed secondary attack rates among susceptible close contacts have varied from 37% to more than 70% (see References: Rao 1968, Arnt 1972, Heiner 1971).
  • The average number of cases infected by a primary case is estimated at 3.5 to 6 (see References: Gani 2001). This observation was consistent across analyses of outbreaks in isolated pre-20th century populations and in 30 outbreaks in 20th-century Europe. In these settings, herd immunity was low. This estimate suggests that in populations with little herd immunity, the transmission potential of smallpox would produce a rapid rise in outbreak cases before control measures could be applied.
  • The period of communicability lasts until all the lesions have scabbed over and the scabs have fallen off. Viable viral particles can be detected in scabs (see References: Wolff 1968; Fenner 1988: Chapter 2); however, scabs are considered relatively noninfectious, since the viral particles are bound in the fibrin matrix of the scab.

Use of Smallpox as a Biological Weapon

  • Smallpox was used as a biological weapon during the French-Indian wars in the United States (1754-1767), when British soldiers gave the Indians blankets that had been used by smallpox patients (see References: Stearn 1945).
  • In 1972, more than 140 countries signed the Biological and Toxin Weapons Convention, which called for termination of all offensive biological weapons research and development and destruction of existing biological weapons stocks.
  • Despite participating in the 1972 convention, the former Soviet Union continued to expand its biological-weapons program throughout the 1980s and early 1990s. During that time, the Soviet Union reportedly developed weaponized variola virus that could be mounted in intercontinental ballistic missiles and bombs for strategic use (see References: Alibek 1999). A recent report from the Center for Nonproliferation Studies suggests that a 1971 outbreak of smallpox in Kazakhstan involving 10 people (three of whom died) may have resulted from an open-air test of a Soviet smallpox biological weapon on Vozrozhdeniye Island in the Aral Sea (a top-secret Soviet bioweapons testing site) (see References: Tucker 2002).
  • Currently, variola virus is known to be stored in two facilities (at the CDC in Atlanta and at the Russian State Centre for Research on Virology and Biotechnology, Koltsovo, Novosibirsk Region, Russian Federation).
  • In the early 1980s, WHO recommended that all existing stocks of variola virus held in other countries be either destroyed or shipped to one of the two WHO-approved collaborating centers. All countries reported compliance; however, there has been no systematic way to assure that all countries actually did comply with the WHO recommendations (see References: Henderson 2001). Also, there is no way to be certain that the virus has not fallen into the hands of rogue nations or potential terrorists (see References: Henderson 1998).
  • On several occasions, WHO has recommended that the remaining stores of variola virus be destroyed (see References: Johns Hopkins Center for Civilian Biodefense Studies). However, in December 2001, the WHO Advisory Committee on Variola Virus Research recommended that existing stocks of the virus be retained for the time being so that various research goals can be achieved (see References: WHO 2001).
  • Smallpox is of concern as a biological weapon for several reasons: much of the population is susceptible to infection, the virus carries a high rate of morbidity and mortality, vaccine is not yet available for general use, and past experience has demonstrated that introduction of the virus creates a great deal of havoc and panic (see References: Henderson 1998, O'Toole 2002).

Back to top

Clinical Features of Variola Major

Variola major can be further classified into five clinical types on the basis of differences in rash characteristics and density; the prognosis differs among the types (see References: Fenner: Chapter 1). These are:

  • Ordinary smallpox
  • Flat-type (or malignant) smallpox
  • Hemorrhagic smallpox
  • Modified smallpox
  • Variola sine eruptione

In the pre-eradication era, diagnosing smallpox and distinguishing its type took into account clinical illness pattern, epidemiologic considerations, and laboratory findings. Although there is some overlap between ordinary, flat-type (or malignant) and hemorrhagic smallpox, their clinical and epidemiologic features are sufficiently distinct to warrant separate consideration (see below), particularly to enhance clinicians' awareness of the various clinical manifestations of what should be an extinct disease.

Modified smallpox was like ordinary smallpox but had an accelerated course and was a milder illness with fewer skin lesions and a low case-fatality rate; it was more likely to occur in persons with some immunity from past vaccination. Variola sine eruptione occurred in vaccinated contacts of cases and was characterized by sudden onset of fever, headache, and backache. Illness resolved in 1 to 2 days without development of a rash.

Case-fatality rates in the pre-eradication era for the various types of smallpox were high; however, such rates may be lower with modern medical management and intensive care.

Images of smallpox rashes are available from CDC and WHO (see References: CDC: Smallpox: rash illness images; WHO: Smallpox: rash illness slideset).

Ordinary Smallpox

  • Ordinary smallpox was the most common form of variola major infection and accounted for at least 90% of cases in the pre-eradication era.
  • The case-fatality rate was usually about 30% in unvaccinated persons (range, 15% to 45%) (see References: Fenner 1988: Chapter 1). Death resulted from hypotension and toxemia (associated with circulating immune complexes).
  • The rash illness of ordinary smallpox is somewhat similar to varicella, although disease severity is greater (see References: Henderson 1999: Smallpox: clinical and epidemiologic features).
  • The rash consists of firm, raised pustules and can be confluent, semiconfluent, or discrete.

Clinical features are shown in the table below.

Clinical Features of Ordinary Smallpox

Feature

Characteristics

Incubation period*

-10-13 days (usually about 12 days)
-May be as short as 7 days and as long as 19 days

Prodrome

-Lasts 2-4 days
-Frequency of prodromal symptoms in one large case series†:
   ~Fever, 100%
   ~Chills, 60%
   ~Headache, 90%
   ~Backache, 90%
   ~Vomiting, 50%
   ~Pharyngitis, 15%
   ~Abdominal pain, 13%
   ~Diarrhea, 10%

Rash*

-Enanthem on mucosa of mouth and pharynx usually begins about 24 hr before skin lesions appear (initially papular, then vesicular, then ulcerative over several days)
-First few skin lesions often appear on face ("herald spots")
-Lesions spread to trunk and proximal extremities and then to distal extremities
-Lesions prominent on face and distal extremities, including palms and soles, in centrifugal pattern
-Lesions initially maculopapular (days 1-2), then vesicular (days 3-5), then pustular (days 7-14); pustules gradually scab over by end of second week or during third week
-Vesicular lesions often have central umbilication which may persist into pustular stage, but as lesions progress they gradually flatten
-Pustules often described as "shotty" (ie, like hard, round foreign bodies embedded in skin)
-Lesions extend deep into skin, often are painful, and pitted scarring occurs as they heal
-Lesions may be discrete (relatively few in number), semiconfluent, or confluent
-Lesions generally progress at same rate with relatively synchronous onset
-In partially immune persons, clinical course may be much less severe and rash may be atypical with fewer lesions and more rapid healing (ie, "modified smallpox")

Laboratory features*

-Relative or absolute increase in lymphocytes may be noted
-Granulocytopenia may occur

Complications†‡

-Massive amounts of subcutaneous fluid may accumulate during vesicular and pustular stages of rash, leading to severe fluid and electrolyte disturbances, including renal failure
-Massive skin desquamation can occur in cases of confluent disease; patients may clinically and metabolically resemble severe burn victims
-Viral bronchitis/pneumonitis occurs relatively commonly
-Other less common complications:
   ~Corneal ulceration (about 1% of cases) and/or keratitis (about 0.25% of cases)
(may cause corneal scarring and blindness)
   ~Secondary bacterial infections (particularly skin and pulmonary infections)
   ~Encephalitis (0.2% of cases)
   ~Osteomyelitis or arthritis (about 1.7% of cases; usually in children)
   ~Orchitis (rare, 0.1%)

Case-fatality rates§

-Overall case-fatality rate for ordinary smallpox, 15%-45%*
-Likelihood of death varies by type of disease (ie, confluent, semiconfluent, or discrete).‡
-Observed case-fatality rates by type of disease among unvaccinated patients in one large series†:
   ~Overall rate, 30%
   ~Confluent disease, 62%
   ~Semiconfluent diseas
   ~Discrete disease, 9%

*SeeReferences: Fenner 1988: Chapter 1.
†See References: Rao 1972.
‡See References: Koplan 1979.
§Case-fatality rates are based on historical data from pre-eradication era; such rates may be lower with modern medical management and intensive care.

Flat-Type (Malignant) Smallpox

  • Flat-type smallpox accounted for about 6% of cases in the pre-eradication era and occurred most commonly in children; illness was usually fatal.
  • The rash seen in flat-type smallpox involves flattened, confluent lesions rather than the characteristic firm pustules seen with ordinary smallpox.
  • Flat-type smallpox is thought to be associated with a deficient cellular immune response to the virus, although immunologic data are generally lacking (see References: Henderson 1999: Smallpox as a biological weapon).

Clinical features are shown in the table below.

Clinical Features of Flat-Type Smallpox

Feature

Characteristics

Incubation period

-Similar to ordinary smallpox (mean, 12 days; usual range, 10-14 days)

Prodrome

-Similar to ordinary smallpox (ie, fever, headache, backache, abdominal pain)
-Lasts 2-4 days
-Severe toxemia may occur

Rash illness*†

-Lesions develop slowly
-Lesions rarely progress to pustular stage but remain soft and flattened
-Lesions may be "velvety" to touch by 4th or 5th day
-Lesions often confluent
-Lesions and surrounding skin warm to the touch and tender to slight pressure
-If patient survives, lesions gradually disappear without forming scabs and without scarring
-Skin peeling or desquamation may occur as lesions heal

Laboratory features

-Similar to ordinary smallpox
-Relative or absolute increase in lymphocytes may be noted
-Granulocytopenia may occur

Case-fatality rate‡

- Case-fatality rate 97% in one series involving 236 patients§

*SeeReferences: Fenner 1988: Chapter 1.
†SeeReferences: Dixon 1948.
‡Case-fatality rates are based on historical data from the pre-eradication era; such rates may be lower with modern medical management and intensive care.
§See References: Rao 1972.

Hemorrhagic Smallpox

  • Hemorrhagic smallpox was rare and accounted for between 2% and 3% of cases in the pre-eradication era. In one series, 200 cases occurred out of 6,942 hospitalized patients (see References: Rao 1972).
  • Illness was more common in adults, and pregnant women appeared to be at greater risk.
  • Hemorrhagic smallpox involved hemorrhages into the skin and/or mucous membranes. Early-onset and late-onset forms were described (see References: Fenner 1988: Chapter 1).
  • The pathologic features of hemorrhagic smallpox are consistent with disseminated intravascular coagulation (see References: Mitra 1976, Mehta 1967).
  • As with malignant smallpox, a defective immune response is suspected as the cause; however, immunologic data generally are lacking (see References: Henderson 1999: Smallpox as a biological weapon). Several studies have found lower antibody responses among patients with hemorrhagic disease compared with those with ordinary disease (see References: Sarkar 1967, Downie 1969).

Clinical features are outlined in the table below.

Clinical Features of Hemorrhagic Smallpox

Feature

Characteristics

Incubation period

-Similar to ordinary smallpox (mean, 12 days; usual range, 10-14 days).

Prodrome*

-Early-onset form: illness onset sudden, with high fever, severe headache and backache, and toxemia; hemorrhages often noted by day 2
-Late-onset form: illness begins with a typical prodrome, lasting 3-4 days

Rash illness*†

-Early-onset form: generalized dusky erythema, petechiae, and ecchymoses occur soon after illness onset
-Late-onset form: lesions begin as macules and develop into pustules; bleeding at base of skin lesions occurs

Hemorrhagic manifestations

-In both forms, bleeding may occur from mucosal surfaces
-Features in one series of nine patients with early-onset form‡:
   ~Subconjunctival hemorrhage, 67%
   ~Hematuria, 56%
   ~Epistaxis, 33%
   ~Hematemesis and/or melena, 33%
   ~Hemoptysis, 33%
   ~Bleeding from gums, 33%

Laboratory features‡§

-Relative or absolute increase in lymphocytes may be noted
-Granulocytopenia may occur
-Features consistent with disseminated intravascular coagulation are common:
   ~Thrombocytopenia
   ~Hypofibrinogenemia
   ~Clotting-factor deficiency
   ~Prolonged prothrombin time

Case-fatality rate**

-In one series of 85 patients, case-fatality rate was 96%.†
-Death usually occurs during the first week of illness

*See References: Fenner 1988: Chapter 1.
†See References: Rao 1972.
‡See References: Mitra 1976.
§See References: Mehta 1967.
**Case-fatality rates are based on historical data from pre-eradication era; such rates may be lower with modern medical management and intensive care.

Smallpox in Children

The clinical picture of smallpox in children generally is similar to that seen in adults. However, in one series of 100 cases among children in India, the frequency of various signs and symptoms varied somewhat from those classically described (see References: Sheth 1971). For example, headache and backache were less common, whereas vomiting, conjunctivitis, and cough were somewhat more common. Signs, symptoms, and complications identified in that series are shown in the table below. Of the 100 patients, 66 had confluent disease, 25 had discrete disease, six had flat-type smallpox, and three had hemorrhagic smallpox. Overall, 34 children died (including all of those with flat-type or hemorrhagic smallpox).

The case-fatality rate in infants may be somewhat higher than in older children or adults (ie, >40%) (see References: Fenner 1988: Chapter 1). In one case series, the case-fatality rate for infants was 85% (see References: Guha Mazumder 1975).

Infection in pregnant women often leads to premature labor and death of the fetus (see References: Fenner 1988: Chapter 1). No clear congenital syndrome has been associated with smallpox infection in utero.

Signs, Symptoms, and Complications of Smallpox in Children

Symptoms

Headache (15%)
Backache (15%)
Retro-orbital pain (15%)
Prostration (75%)

Signs

Fever (100%)
Vomiting (83%)
Conjunctivitis (77%)
Hepatosplenomegaly (75%)
Hypotonia (75%)
Cough (71%)
Hoarseness (71%)
Edema (71%)
Delerium (64%)
Convulsions (7%)

Complications

Constipation (66%)
Bronchopneumonia (37%)
Alopecia (19%)
Osteomyelitis (4%)
Subcutaneous abscess (3%)
Diarrhea (2%)

Adapted from Sheth 1971 (see References).

Back to top

Clinical Features of Variola Minor

Variola minor is a milder form of smallpox that is caused by distinct strains of variola virus. Variola minor was first recognized in the late 1800s; during the early 20th century, it was the most prevalent form of smallpox in the United States and Great Britain. The illness may be difficult to distinguish from variola major infection in partially immune persons.

Distinguishing Features of Variola Major and Variola Minor

Feature

Variola Major

Variola Minor*†

Prodrome

-Constitutional symptoms severe

-Constitutional symptoms tend to be mild

Rash illness

-Lesions often confluent or semiconfluent
-Rash evolves over 2-3 wk

-Lesions usually discrete
-Rash evolves over 1-2 wk

Complications

-Flat-type or hemorrhagic disease occurs more commonly (6% and 2%, respectively, in one large series‡)

-Hemorrhagic disease rare (<0.5%)

Case-fatality rate

-May be high (15%-45%)

-Fatal outcomes rare (<1%)

*See References: Fenner 1988: Chapter 1.
†See References: Ker 1967, Marsden 1948.
‡See References: Rao 1972.

Back to top

Differential Diagnosis

Differential Diagnosis of the Rash illness

Other rash illnesses, outlined in the table below, are included in the differential diagnosis of smallpox.

Differential Diagnosis for Smallpox

Condition

Agent

Distinguishing features

Ordinary Smallpox*

Chickenpox

VZV

See Distinguishing Features of Smallpox and Chickenpox below

Human monkeypox

Monkeypox virus

See Monkeypox below

Disseminated herpes zoster

VZV

-Usually occurs in immunocompromised hosts
-Past history of chickenpox

Impetigo

Staphylococcus aureus
Streptococcus pyogenes

-Lesions often pruritic and not painful
-Lesions focal and not usually disseminated
-Lesions not "shotty"
-Gold-colored crusted plaques are classic
-Lesions superficial and not embedded into dermis
-Constitutional symptoms generally absent or minimal
-Usually occurs in children

Hand, foot, and mouth disease

Coxsackievirus

-Usually occurs in children <10 yr of age
-Has autumn seasonal pattern
-Lesions may be confined to hands and feet (although dissemination may occur)

Disseminated herpes simplex

Herpes simplex virus

-Usually occurs in immunocompromised hosts
-Lesions are vesicular and do not progress to pustules

Secondary syphilis

Treponema pallidum

-Rash generally does not include vesicular phase
-Lesions not "shotty"
-Constitutional symptoms relatively mild
-Lesions generally evolve slowly from macules to papules to pustules (often over several weeks)

Molluscum contagiosum

Molluscipoxvirus

-Usually occurs in healthy children or HIV-positive adults
-In healthy adults, lesions generally occur in genital area
-Lesions are painless
-Constitutional symptoms generally are absent
-Lesions may persist for several months (or longer in immunocompromised patients)

Erythema multiforme major (including Stevens-Johnson syndrome)

Associated with various infectious and noninfectious processes

-Constitutional symptoms and rash usually appear at same time
-Rash evolves rapidly
-Bullae or "bull's-eye" lesions common
-Extensive mucous membrane involvement, including conjunctivitis, common

Drug eruptions

Noninfectious

-Lesions generally not pustular
-History of drug exposure
-Fever may be present, but severe toxemia usually absent

Bullous pemphigoid

Noninfectious

-Tense bullae characteristic
-Occurs most commonly in elderly
-Intense pruritis may be present
-Constitutional symptoms usually absent
-Peripheral eosinophilia may be noted

Hemorrhagic Smallpox

Meningococcemia

Neisseria meningitidis

-Rapid progression to shock and often death

Hemorrhagic varicella

VZV

- Usually occurs in immunocompromised children

Rocky mountain spotted fever

Rickettsia rickettsii

-Tick exposure history may be obtained
-Occurs April through May
-Most US cases occur in southeastern and south-central states

Ehrlichiosis

Ehrlichia chaffeensis
Erhlichia phagocytophilia

-Tick exposure history may be obtained
-Petechial rash uncommon
-Peripheral blood smear may show morulae in neutrophils of patients with human granulocytic ehrlichiosis

Septicemia caused by gram-negative bacteria

Various bacterial agents

-Underlying illness usually present

Abbreviation: VZV, varicella-zoster virus.
*Other rash illnesses (eg, measles, rubella, contact dermatitis, scabies) also may be considered in the differential diagnosis, although the rashes caused by these conditions generally are not characteristic of smallpox or are localized.
Adapted from Fenner 1988: Chapter 1, and CDC: Generalized vesicular or pustular rash illness protocol (see References).

Distinguishing Features Between Smallpox and Chickenpox

Smallpox and chickenpox cause somewhat similar illnesses, although smallpox generally is much more severe. However, smallpox in partially immune patients may be mild and may resemble chickenpox.

Early in the clinical course, smallpox may be mistaken for chickenpox if the clinical suspicion for smallpox is low. Distinguishing features of the two illnesses are outlined in the table below.

Distinguishing Features Between Smallpox and Chickenpox

Feature

Smallpox (Variola Major)*

Chickenpox

Prodrome

Lasts 2-4 days, with high fever, headache, backache, severe prostration; vomiting and severe abdominal pain may occur

Prodrome often absent; if present, it is mild and brief (ie, about 1 day)

Distribution of rash

Begins on oral mucosa, spreads to face, then expands in centrifugal pattern (ie, most dense on face and distal extremities)

Begins on trunk and expands in centripetal pattern (ie, most dense on trunk)

Lesions on palms and soles

Common

Almost never occur

Timing for occurrence of lesions

Generally emerge over 1-2 days and then progress at same rate

Occur in "crops" and may be at different stages of maturation at any given point in time

Evolution of lesions

Progress over several days from macules (day 1), to papules (day 2), to vesicles (days 3-5), to pustules (days 7 to about 14), to scabs (day 14 to about 20)

Progress quickly over about 24 hr from macules to papules to vesicles, then to crusted lesions

Sensation associated with lesions

May be painful and only become pruritic during scabbing stage

Often intensely pruritic; not usually painful unless superimposed bacterial infection occurs

Depth of lesions

Extend deep into dermis and often cause pitted scarring

Superficial and generally do not cause scarring

Duration of illness

14-21 days

4-7 days

Severity

Patients often appear toxic and case-fatality rate may be as high as 50%

Patients often do not appear severely ill and illness is rarely fatal

Epidemiology

Cases can be expected to occur in all age-groups; illness may be somewhat milder in adults over age 30 who were vaccinated as young children

Most cases occur in children; adults likely to be immune

*Illness may be milder in patients with partial immunity; fever may be less common and fewer lesions may occur with more rapid healing.
Adapted from CDC: Generalized vesicular or pustular rash illness protocol (see References).

Monkeypox

  • Human monkeypox is caused by monkeypox virus, which (like variola virus) is in the Orthopoxvirus genus.
  • The illness in humans is similar to discrete or semiconfluent ordinary smallpox (see References: Jezek 1987). A prodrome (fever, headache, backache) lasting 1 to 3 days occurs, followed by eruption of a smallpox-like rash that lasts 2 to 4 weeks.
  • Monkeypox cases tend to have prominent lympadenopathy, which generally is not a feature of either chickenpox or smallpox (see References: Arita 1985, Breman 1980, Jezek 1987).
  • The illness occurs naturally only in Western and Central Africa. Animal reservoirs include several squirrel species and forest-dwelling primates (see References: Khodakevich 1988).
  • The first human case was recognized in 1970; since then sporadic cases and outbreaks have been recognized, although the illness appears to be relatively uncommon.
  • The case-fatality rate was 11% in one series of 282 patients (see References: Jezek 1987) and was 3% in one outbreak involving 71 cases (see References: CDC: Human monkeypox), suggesting that the illness is less severe than smallpox. In both investigations, all deaths occurred in children less than 10 years of age (who had not received earlier smallpox vaccination).
  • Person-to-person transmission has been demonstrated (see References: Arita 1985; Breman 1980; CDC: Human monkeypox; Jezek 1986; Jezek 1988). Secondary attack rates of 7.2%, 7.5%, and 15% have been reported among household contacts who had not received prior smallpox vaccination (see References: Arita 1985, Jezek 1986, Jezek 1988). These secondary attack rates are lower than those observed for smallpox and reflect the lower propensity for spread of monkeypox compared with smallpox.

Back to top

Diagnostic Issues

Criteria for Determining the Likelihood of Smallpox

The likelihood of a smallpox diagnosis determines the appropriate laboratory testing and handling of specimens. CDC has developed criteria for determining the risk of smallpox (see References: CDC: Generalized vesicular or pustular rash illness protocol).

High risk for smallpox (when all three of the following features are present):

  • Febrile prodrome (occurring 1 to 4 days before rash onset) with fever greater than 102°F and at least one of the following:
    • Prostration
    • Headache
    • Backache
    • Chills
    • Vomiting
    • Severe abdominal pain
  • Classic smallpox lesions:
    • Deeply embedded in the dermis
    • Firm/hard
    • Round
    • Well-circumscribed
    • May be umbilicated
    • May be discrete, semiconfluent, or confluent
  • Lesions in the same stage of development (ie, on any one area of the body, all of the lesions are at the same stage [all lesions are papules or vesicles or pustules])

Moderate risk for smallpox:

  • Febrile prodrome (as outlined above under "High risk for smallpox") and at least one major smallpox criteria (classic smallpox lesions as described above or lesions in the same stage of development) or
  • Febrile prodrome and at least four of the five minor criteria:
    • Centrifugal distribution (lesions are more numerous on the face and distal extremities)
    • First lesions appeared on the oral mucosa/palate, face, or forearms
    • Patient appears toxic or moribund
    • Slow evolution of lesions from macules to papules to pustules over several days
    • Lesions on the palms and soles

Low risk for smallpox:

  • No viral prodrome or
  • Febrile prodrome and fewer than four of the five minor criteria outlined above (under "Moderate risk for smallpox")

Specimen Collection and Handling

Collection
  • If a patient is defined as high risk for smallpox (see Criteria for Determining the Likelihood of Smallpox above), physicians should immediately contact their local or state health department for further instructions before collecting specimens.
  • CDC has recently outlined procedures for collecting specimens from patients who may have smallpox (see References: CDC: Interim smallpox response plan and guidelines: Guide D).
  • Only recently vaccinated (ie, within the past 3 years) personnel wearing appropriate barrier protection (ie, gloves, gown, shoe covers) should be involved in specimen collection.
  • If unvaccinated personnel must collect specimens, they should wear fit-tested N95 respirators and appropriate barrier protection. They also should have no contraindications to vaccination in case the diagnosis of smallpox is confirmed and vaccination is immediately required.

The following table outlines collection of laboratory specimens for the diagnosis of smallpox.

Collection of Laboratory Specimens for the Diagnosis of Smallpox

Sample

Specimen Collection

Vesicles or pustules

-Use scalpel (or 26-gauge needle) to open and remove top of vesicle or pustule, place skin of vesicle top into a 1.5- to 2-mL screw-capped or plastic tube, let dry.
-Scrape base of vesicle or pustule with blunt edge of scalpel or with wooden end of an applicator stick or swab, make touch prep by applying vesicular fluid to a microscope slide with progressive movement of slide, and air dry 10 min.
-Store dried slides in plastic slide holders, using a different holder for each patient.
-If a slide is not available, swab base of lesion with a polyester or cotton swab, place in screw-capped plastic vial, break off applicator handle, and screw on lid (do not add transport medium to the vial).
-If available, touch an electron microscope grid to unroofed base of lesion and air dry (repeat two times); place in gridbox.
-Biopsy two vesicles with 3.5- or 4-mm punch biopsy kit; place one biopsy in formalin and one in 1.5- to 2-mL screw-capped container without added fluid.
-Draw 10 cc blood into plastic marble-topped tube or plastic yellow-topped serum separator tube; if plastic tubes not available, use equivalent glass tubes and package with styrofoam protector (Note: central line sample may be needed if peripheral blood draw is difficult because of sloughing skin in dense rash area).
-Swab or brush posterior tonsillar tissue and package in 1.5- to 2-mL tube, as above (do not add transport medium).
-Draw 5 cc blood into plastic purple-topped tube, gently shake tube to mix contents (if plastic not available, use glass as described above)

Scab lesions

-Use 26-gauge needle to pry off at least four scabs.
-Place two scabs in each of two screw-capped plastic 1.5- to 2-mL vials.
-Obtain two biopsy specimens with a 3.5- or 4-mm punch biopsy kit; place one in formalin and one in 1.5- to 2-mL screw-capped container.
-Draw 10 cc blood into plastic marble-topped tube or plastic yellow-topped serum separator tube as described above.
-Collect swab of tonsillar tissue as described above.
-Draw 5 cc blood into plastic purple-topped tube as described above.

Autopsy specimens

-Ship frozen portions of skin-containing lesions, liver, spleen, lung, lymph nodes, and/or kidney.
-Collect formalin-fixed tissue from skin-containing lesions, liver, spleen, lung, lymph nodes, and/or kidney; package separately from frozen fresh tissue and ship at room temperature.
-Use plastic vials, bottles, or slide holders as primary container for all specimens.

Adapted from CDC: Interim smallpox response plan and guidelines: Guide D (see References).

Handling and Shipping

Storage and shipping conditions:

  • Store and ship at room temperature for samples in formalin, 4oC for electron microscope grids and serum, and -20oC to -70oC (dry ice) for fresh biopsy material.
  • Other samples should be stored and shipped at 4oC if shipped within 24 hours of collection and at -20o C to -70o C (dry ice) if held for longer periods of time.
  • Seal vials with parafilm to avoid pH changes from dry-ice vapors.
  • If there will be a delay in shipping, spin serum to separate from clot, then store and ship at 4oC.

Packaging:

  • Package one sample per container.

Transport:

  • Contact CDC to obtain specific instructions for transporting specimens.

Back to top

Laboratory Diagnosis

Laboratory Response Network (LRN)

The LRN has been developed in the United States to coordinate clinical diagnostic testing for bioterrorism events (see References: CDC: Emergency response; CDC: Biological and chemical terrorism; Gilchrist 2001). The network is organized into four laboratory levels (A, B, C, and D). Level D laboratories must meet BSL-4 criteria; currently, the only laboratories so designated are at the CDC and the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The LRN can be accessed by contacting local or state public health laboratories.

  • All testing of samples from patients at high risk for smallpox should be performed by Level D laboratories only (see Criteria for Determining the Likelihood of Smallpox above and see References: CDC: Biosafety in microbiological and biomedical laboratories).
  • Testing for rash illness (such as varicella-zoster virus testing) on specimens from patients not at high risk for smallpox (see Criteria for Determining the Likelihood of Smallpox above) can be performed at other laboratory levels that have at least BSL-2 containment facilities. If smallpox cannot be ruled out through other testing, the local or state health department should be contacted for further instructions.
  • Level C laboratories are expected in the near future to have the ability to conduct testing for smallpox on inactivated samples using such methods as polymerase chain reaction (PCR) and electron microscopy.

Tests for Detection and Identification of Variola Virus

  • Culture on egg chorioallantoic membrane (CA): This is the classical method for identification of poxviruses and was used extensively before the eradication of smallpox. Poxviruses grow on CA, and each species forms characteristic pock lesions under defined temperature conditions (see References: Fenner 1988: Chapter 2).
  • Direct examination of vesicle or pustular material: As one of the largest viruses known, variola virus may be seen in the cytoplasm of Giemsa- or silver-stained cells viewed by light microscopy. This was used in the past in outbreak settings and is not significant today per se but remains important because poxviruses may be inadvertently discovered in the laboratory (see References: Fenner 1988: Chapter 2).
  • Tissue culture: Growth in cultured cells has been used for quantitative culture of variola virus, and attempts have been made to characterize its cytopathic effect for identification purposes (see References: Marennikova 1974, Fenner 1988). As with direct examination by light microscopy, this is important because current tissue culture methods may result in inadvertent discovery.
  • Electron microscopy: Negative staining is used to visualize the characteristic large brick shape and fine structure detail of poxviruses. Electron microscopy by itself is insufficient for definitive identification of variola virus, but can be useful to distinguish poxviruses that infect humans (eg, variola, vaccinia, cowpox, monkeypox) from varicella-zoster virus.
  • PCR-based methods: These have been developed to detect and identify poxviruses (see References: Ropp 1995).
  • DNA probe: A method for identifying orthopoxviruses to the species level, using an oligonucleotide microchip, has been described (see References: Lapa 2002).
  • Serology: Classical methods such as complement fixation and gel precipitation commonly were used in the past. Experimental enzyme-linked immunoassays are currently being evaluated (see References: LeDuc 2001).
  • Strain identification: A restriction fragment length polymorphism assay (RFLP) has been developed by CDC using polymorphisms found on 45 variola strains from 1939 to the 1970s (see References: Le Duc 2001).
  • Antiviral susceptibility testing: USAMRIID is developing animal models for evaluating antiviral drugs; this testing is being conducted at the CDC BL-4 facility (see References: LeDuc 2001).

Rapid Tests for Diagnosis of VZV and HSV

Laboratories that have at least BSL-2 containment facilities can perform rapid tests for diagnosis of rash illness in patients not considered at high risk for smallpox (see Criteria for Determining the Likelihood of Smallpox above). The most likely alternative agents are varicella-zoster virus (VZV) and herpes simplex virus (HSV); available rapid tests for these two agents include the following:

  • Cytology smears: Tzanck preparations stained with Giemsa or Papanicolaou stain are rapid, inexpensive, and 80% sensitive by one study (see References: Cohen 1994, Oranje 1986, Gershon 1999).
  • Direct fluorescent antibody (DFA): An assay by Chemicon (see References: Chemicon, Inc) detects VZV and HSV simultaneously. A recent study shows a sensitivity of 80% and specificity of 98.3% for HSV with same-day turnaround. A shell vial direct immunoperoxidase assay had a sensitivity of 87.6% and a specificity of 100%, and a turnaround time of 1 to 2 days. With VZV-positive samples, the DFA had a correlation of 87.1% with a cytospin DFA method (see References: Chan 2001).
  • Standard PCR methods: PCR has been shown to be more sensitive than immunofluorescence for detection of VZV (see References: Bezold 2001) and significantly more sensitive than electron microscopy (see References: Jain 2001). PCR has been shown to detect HSV and VZV effectively from Tzanck smears and vesicle fluid but less effectively from fixed-tissue specimens (see References: Nahass 1995). FDA-approved methods are not yet available.
  • "Real time" PCR assays: Rapid PCR assays using TaqMan and LightCycler technologies have been developed for HSV and VZV. These assays appear to have very high sensitivity and specificity. In some studies, assay sensitivity is higher than culture sensitivity (see References: Espy 2000, Hawrami 1999, Ryncarz 1999, Aldea 2002, Koenig 2001, Nicoll 2001). FDA-approved methods are not yet available.

Testing in Areas With Confirmed Smallpox

Once smallpox is confirmed in a geographic area, additional cases can be diagnosed clinically (see References: CDC: Interim smallpox response plan and guidelines: Guide A).

In such situations, laboratory resources will be used for specimen testing in the following cases:

  • Those in which clinical presentation is unclear
  • Those that will provide information about a potential source of exposure
  • Those that will facilitate law enforcement activities or case detection

Inadvertent Discovery of Variola Virus in a Laboratory Specimen

Variola virus and other poxviruses grow readily on many cell lines such as Vero, HeLa, SF, and MRC-5. Accidental discovery of variola virus by a clinical virologist would constitute a danger to the laboratorians and could precipitate unintentional release to the community. The following features of variola virus in cell culture have been described in the older literature (see References: Fenner 1988: Chapter 2; Marennikova 1974; Ono 1968):

  • In human cell lines, variola virus tends to form "hyperplastic foci" as cells are pushed together by growing cells around them.
  • Within 24 to 48 hours, giant multinucleated cells form.
  • When stained, there may be a circular arrangement of nuclei around an eosinophilic part of the cytoplasm, often containing inclusions.
  • Within 72 to 96 hours, the number of giant cells increases, as does degeneration of the cell layer.
  • Variola virus can cause numerous inclusion bodies (Guarnieri bodies) in the cytoplasm of infected cells, which can be viewed after staining by Giemsa, modified silver stain, or other stains. Interpretation was difficult during times of smallpox occurrence and would be more difficult today.

If an unusual cytopathic effect is observed on any cell culture, especially involving giant cells, laboratory personnel should determine the suspected diagnosis for the patient before proceeding with identification. If the patient is at high risk for smallpox or at moderate risk for smallpox without alternate diagnoses, then the cell culture should be sealed, stored securely, and the local or state health department contacted for further instructions. Staining of cells suspected of harboring poxvirus is not recommended.

Back to top

Treatment

Treatment for smallpox largely consisted of general supportive measures:

  • Adequate fluid intake (difficult because of the enanthem)
  • Alleviation of pain and fever
  • Keeping the skin lesions clean to prevent bacterial superinfection

No specific antiviral treatment of demonstrated effectiveness was available in the pre-eradication era.

In recent years, 274 antiviral compounds have been screened for therapeutic activity against variola virus and other orthopoxviruses (see References: Le Duc 2001). Cidofovir as well as 27 other compounds have demonstrated activity against orthopoxviruses, including variola. In advanced clinical testing for other viral infections, cidofovir, adefovir dipivoxil, cyclic cidofovir, and ribavirin have shown significant in vitro activity (see References: Franz 1997). All promising compounds will be further evaluated in animal models.

Back to top

Smallpox Vaccination

Historical Perspective

  • The first efforts at smallpox vaccination involved a process called variolation, which was the deliberate cutaneous inoculation of variola virus via infectious material obtained from smallpox pustules of a patient with active disease (see References: Fenner1988: Chapter 6). Variolation was practiced as early as 1000 AD in China and gradually spread around the globe.
  • Variolation generally resulted in a severe localized reaction, a generalized rash, and constitutional symptoms. The case-fatality rate following variolation was much lower than that following natural smallpox (about 0.5% to 2% and 20% to 30%, respectively) and, therefore, this practice was widely implemented.
  • The variola virus used in variolation was not attenuated, and one of the disadvantages of this practice was that smallpox could be spread to susceptible contacts of a person infected via variolation.
  • In the late 1700s, Edward Jenner successfully used cowpox virus to vaccinate people against smallpox. Because this practice was safer and relatively effective, it rapidly gained wide acceptance and replaced variolation as the primary method of conferring protection against smallpox.
  • Over time, vaccinia virus gradually replaced cowpox virus as the agent used in smallpox vaccine. Vaccinia virus is genetically distinct from cowpox virus, although its origin remains unknown. It may have been derived from cowpox virus initially and modified over time through serial passage in laboratory cultures, or it may represent another orthopoxvirus that is now extinct in nature.

Dryvax Vaccinia Vaccine

  • The vaccinia vaccine that has been available in the United States since the 1970s is a lyophilized preparation of infectious vaccinia virus (Dryvax, manufactured by Wyeth Laboratories, Lancaster, Pennsylvania).
  • Existing Dryvax supplies were produced in the 1970s and have been maintained in lyophilized storage since that time; evaluation has shown that the vaccine is still potent, and it is estimated that there are about 15.4 million doses of Dryvax vaccine currently available (see References: LeDuc 2001).
  • Published data indicate that the current Dryvax vaccine may be diluted 1:5 without significant loss of vaccine potency (see References: Frey 2002: Dose-related effects of smallpox vaccine; Frey 2002: Clinical responses to undiluted and diluted smallpox vaccine). Currently the diluent is prepackaged at a volume of 1.25 mL, affording one-step reconstitution-dilution at a 1:5 dilution with a sufficient margin of excess virus. The aim of diluting vaccine stocks is to substantially extend current supplies, and all existing product is being diluted to the 1:5 ratio. This will bring the existing Dryvax supply to about 77 million doses.
  • Diluting the Dryvax vaccine 1:10 (ie, to a titer of 107.0 plaque-forming units [pfu] per milliliter, or approximately 10,000 pfu/dose) was also capable of eliciting adequate vaccination responses (Frey 2002, as above); however, widespread use of the 1:10 dilution under field conditions would be problematic, as there would be only a narrow margin of excess virus in the vaccine which, with any mishandling, could lead to many failures. Therefore, the vaccine will not be diluted at the 1:10 ratio.
  • CDC is the only vaccine distributor for civilians; current smallpox vaccines are only available under an Investigational New Drug (IND) protocol from CDC's Drug Service [call 404-639-3670] (see References: CDC: Drug Service). The vaccine is only made available for laboratory and healthcare workers who are at risk of exposure to vaccinia viruses and to military personnel. It is not available for the general public.
  • An additional 85 million doses of smallpox vaccine (prepared using the same strain as Dryvax but stored frozen) recently have been located by Aventis and donated to the US government. These vaccine supplies will be held in reserve for use on an as-needed basis.

Information about the efficacy of Dryvax can be found in the 2001 statement on smallpox vaccine from ACIP (see References: CDC: Vaccinia [smallpox] vaccine):

  • Successful primary vaccination is demonstrated by occurrence of a pustular or vesicular skin lesion at the site of vaccination after about 7 days. Successful revaccination (ie, in a person who has received at least one prior dose of vaccine) is indicated by palpable inflammation at the site 6 to 8 days after vaccination (a pustule may or may not be present with revaccination).
  • The presence of a localized skin reaction to vaccination correlates with the development of neutralizing antibody, which appears about 10 days after primary vaccination and about 7 days after revaccination.
  • Neutralizing or hemagglutination inhibition antibody titers of 1:10 or higher will develop in 95% of primary vaccinees. Although the level of antibody required for protection against vaccinia infection has never been fully evaluated in the field, available data suggest that titers of 1:10 or greater will confer protection for most vaccinated persons.
  • The duration of immunity has never been adequately measured. Epidemiologic studies suggest that protection against smallpox persists for 5 to 10 years after primary vaccination. Neutralizing antibody titers of 1:10 or higher are found in 75% of persons up to 10 years after receiving two doses of vaccine and up to 30 years after receiving three doses.
  • It has been estimated that fewer than 20% of persons vaccinated before the early 1970s (when routine vaccination was discontinued in the United States) have immunologic protection today (see References: Henderson 1999: Smallpox as a biological weapon). It is not clear whether a remote history of receiving at least one dose of smallpox vaccine will modulate disease severity in the event that infection occurs.

New Vaccinia Vaccines

  • In September 2000, CDC entered into an agreement with OraVax (since renamed Acambis, Cambridge, Massachusetts) to produce a new cell culture-derived vaccinia vaccine.
  • In October 2001, the federal government contracted with Acambis and Acambis-Baxter for at least 209 million doses of smallpox vaccine produced in cell culture; these doses are expected to be available by the end of 2002 (see References: CDC: Supplemental recommendations of the ACIP).
  • Because the new vaccine has a different method of production, studies to assess vaccine efficacy are needed. Clinical trials are currently under way and should be completed by 2003. Supplies of cell culture-derived vaccine will be made available as needed under an IND protocol from CDC.
  • The vaccine produced by Acambis (ACAM1000) and the vaccine produced by Baxter (ACAM2000) both contain 100 doses per vial, should be stored at 2° to 8°C, and are reconstituted with 0.25 mL of diluent (see References: CDC: Interim smallpox response plan and guidelines: Annex 3).

Recommendations for Use of Vaccinia Vaccines

  • Routine smallpox vaccination in the United States stopped in 1972 for children and in 1976 for healthcare workers. Prior to 1972, smallpox vaccine was recommended for all children in the United States at 1 year of age.
  • Vaccinia vaccination currently is recommended for laboratory workers and certain healthcare workers:
    • Those who directly handle vaccinia virus cultures, contaminated dressings or other infectious material, recombinant vaccinia viruses, or other orthopoxviruses that infect humans (eg, monkeypox)
    • Those who handle animals contaminated or infected with vaccinia virus, recombinant vaccinia viruses, or other orthopoxviruses that infect humans
  • The best strategies for pre- and post-exposure smallpox vaccine deployment for both the general public and potentially high-risk populations recently have been subjects of intense national debate (see References: Fauci 2002, Bicknell 2002). The current CDC strategy for use of the vaccine in outbreak control is outlined under Use of Smallpox Vaccine During a Smallpox Emergency below. In addition, the ACIP made the following recommendations on June 20, 2002 (see References: CDC: Supplemental recommendations of the ACIP: use of smallpox [vaccinia] vaccine):
    • Under current circumstances, with no confirmed smallpox, and the risk of an attack assessed as low, vaccination of the general population is not recommended, as the potential benefits of vaccination do not outweigh the risk of vaccine complications.
    • Smallpox vaccination is recommended for persons pre-designated by the appropriate bioterrorism and public health authorities to conduct investigation and follow-up of initial smallpox cases that would necessitate direct patients contact.
    • Smallpox vaccination is recommended for selected personnel in facilities pre-designated to serve as referral centers to provide care for the initial cases of smallpox. These facilities would be pre-designated by the appropriate bioterrorism and public health authorities, and personnel within these facilities would be designated by the hospital.
  • Vaccinia vaccine should never be used for therapeutic purposes. There is no evidence that it has any value in the treatment of any condition, and use is reserved for prevention of infections caused by human orthopoxviruses.

Vaccination Schedule

  • Vaccination consists of a single dose followed by a booster every 10 years.
  • Revaccination every 3 years (see References: CDC: Vaccinia [smallpox] vaccine) should be considered for persons who work with:
    • Nonhighly attenuated vaccinia viruses
    • Recombinant viruses developed from nonhighly attenuated vaccinia viruses
    • Nonvariola orthopoxviruses such as monkeypox

Dosage and Route of Administration

The vaccine is administered using a droplet of the vaccine applied to a bifurcated needle in the following manner (see References: Fenner 1988: Chapter 11; CDC: Interim smallpox response plan and guidelines: Guide B):

  • Remove the rubber stopper from the vaccine vial and place it in a sterile container.
  • Insert a sterile bifurcated needle into the ampule of reconstituted vaccine and withdraw the needle perpendicular to the floor.
  • Use the outer aspect of the upper right arm over the insertion of the deltoid muscle as the standard vaccination site.
  • Clean the vaccination site only if it is grossly contaminated. If cleaning is necessary, clean the site with alcohol and let dry completely.
  • Hold the needle at a right angle to the skin of the upper arm with the wrist of the vaccinator against the vaccinee's forearm.
  • Make 15 perpendicular strokes of the needle rapidly in an area about 5 mm in diameter. The strokes should be sufficiently vigorous so that a trace of blood appears at the vaccination site after 15 to 30 seconds. If blood does not appear, repeat the procedure.
  • Do not redip the needle into the vaccine vial if the needle has touched the skin.
  • Wipe the excess vaccine and blood from the site with gauze and discard in a hazardous waste receptacle.
  • Cover the site with a loose, nonocclusive dressing to prevent autoinoculation of another body site (historically, this was the most common complication of vaccination in the United States).
  • If the vaccine is to be stored for subsequent use, recap the vial with the sterile rubber stopper and store the capped vial at 2°C to 8°C.

Local Reaction to Vaccination

Upon primary vaccination, all recipients experience a local reaction to the vaccine. A typical reaction occurs in the following sequence:

  • About 3 days after vaccination, a red papule appears at the vaccination site.
  • By day 5, the papule becomes vesicular.
  • By day 7, it becomes a typical "jennerian" pustule (whitish, umbilicated, multilocular, containing turbid fluid, and surrounded by an erythematous areola that may continue to expand for 3 more days).
  • The pustule eventually dries, leaving a dark crust that normally falls off after about 3 weeks.
  • Regional lymphadenopathy and fever are common.

Cutaneous reactions to subsequent vaccinations are weaker and manifest a range of the local reactions above. For a revaccination to be considered successful, palpable inflammation or a pustule must be present. With revaccination, the less intense the "jennerian" pustule, the greater the likelihood of some degree of residual immunity. No reaction to revaccination indicates inadequate technique or insufficient virus in the inoculation.

Contraindications and Precautions

Vaccinia vaccine for pre-exposure use is contraindicated for:

  • Persons with a history of eczema (even if the condition is mild or not presently active) or other significant exfoliative skin conditions, because the risk of eczema vaccinatum is increased in this group
  • Persons with conditions causing immunodeficiency (eg, HIV infection, leukemia, lymphoma, generalized malignancy, agammaglobulinemia or other hereditary immunodeficiency, or therapy with alkylating agents, antimetabolites, radiation, or large doses of corticosteroids)
  • Persons with household contacts who are immunodeficient or who have a history of eczema
  • Pregnant women
  • Persons with hypersensitivity reactions to vaccine components, including polymyxin B sulfate, streptomycin sulfate, chlortetracycline hydrochloride, and neomycin sulfate

If routine pre-exposure smallpox vaccination were reintroduced, a recent study estimated that up to 25% of the US population would be excluded from vaccination, either because of a direct contraindication or the potential to expose high-risk household members (see References: Kemper 2002).

Adverse Reactions

Serious adverse reactions to smallpox vaccination can occur; these are outlined in the following table. Not all of these reactions can be successfully treated with vaccinia immune globulin (VIG). For images of smallpox vaccine reactions, see References: CDC: Smallpox: vaccine reaction images).

A pre-exposure smallpox vaccination campaign for the US general public aged 1 to 65 could result in as many as 4,600 serious adverse events and 285 deaths (excluding high-risk persons and their contacts) (see References: Kemper 2002).

Rates of Adverse Reactions Associated With Smallpox Vaccination Among Primary Vaccinees and Revaccinees

Adverse Reaction

Rate for Primary Vaccinees (per million vaccinations)

Rate for Revaccinees (per million vaccinations)

Description

Inadvertent inoculation of other body sites

529.2

42.1

-Common sites include face, eyelid, nose, mouth, genitalia, and rectum

Generalized vaccinia

241.5

9.0

-Characterized by vesicular rash (can range from a few lesions to generalized reaction)
-Occurs 6- 9 days after vaccination
-Condition usually self-limited

Eczema vaccinatum

38.5

3.0

-Condition caused by localized or systemic dissemination of vaccinia virus in persons with preexisting eczema and other chronic or exfoliating skin conditions
-Vaccinial skin lesions cover all or most of the area once or currently afflicted by eczema
-Condition usually mild and self-limited but may be severe and occasionally fatal

Progressive vaccinia

1.5

3.0

-Vaccinial lesion fails to heal and progresses to involve adjacent skin with associated tissue necrosis
-Area of necrosis can spread to other parts of skin, to bones, and to viscera
-Is frequently a fatal complication for immunodeficient persons

Postvaccinial encephalitis

12.3

2.0

-Clinical presentation includes fever, headache, vomiting, and drowsiness and may include meningitic signs and symptoms, coma, and convulsions
-Most cases occur in primary vaccinees <1 yr of age
-5%-25% of patients die, and an additional 25% have permanent neurologic damage

Adapted from CDC: Vaccinia (smallpox) vaccine, and Lane 1970 (see References).

Treatment of Adverse Reactions With Vaccinia Immune Globulin (VIG)

  • VIG, manufactured by Baxter Healthcare Corporation, is the only product currently available to treat complications of vaccinia vaccination.
  • VIG is available only from the CDC.
  • VIG is an isotonic sterile solution of the immunoglobulin fraction of plasma from persons vaccinated with vaccinia vaccine.
  • Currently, enough VIG is available to treat about 600 serious adverse reactions (see References: CDC: Supplemental recommendations of the ACIP: use of smallpox [vaccinia] vaccine, June 2002). Because the availability of VIG is limited, its use should be reserved for the most serious cases. Contracts for additional VIG supplies are in progress.
  • The currently available VIG preparation is administered intramuscularly in a dose of 0.6 mL/kg. Because the dosage is large, the product is given in divided doses over a 24- to 36-hour period and may be repeated if necessary at 2- to 3-day intervals.

Indications for use of VIG are outlined in the table below.

Indications for Use of Vaccinia Immunoglobulin (VIG) for Treatment of Adverse Reactions Associated With Smallpox Vaccination

Adverse Reaction

VIG Indication

Inadvertent inoculation of other body sites

-Usually not required
-Indicated for inoculation of eye or eyelid if vaccinial keratitis not present
-Contraindicated for vaccinial keratitis because increased scarring can occur

Generalized vaccinia

-Indicated if patient is toxic or if patient has serious underlying illness

Eczema vaccinatum

-Indicated for severe cases

Progressive vaccinia

-Indicated for severe cases

Postvaccinial encephalitis

-Not effective

Adapted from CDC: Vaccinia (smallpox) vaccine (see References).

Use of Vaccine for Postexposure Prophylaxis

  • Immunity to variola virus generally develops within 8 to 11 days after vaccination. Since the incubation period for smallpox averages about 12 days, vaccination soon after exposure (ie, within 4 days) may confer some immunity to exposed persons and reduce the likelihood of a fatal outcome.
  • Postexposure vaccination may be particularly useful for persons who have received a dose of vaccine at some point in the past, since such persons are more likely to mount an anamnestic immune response with revaccination (see References: Henderson: Smallpox as a biological weapon).
  • Studies on the utility of postexposure vaccination have shown conflicting results. Examples of study findings include the following:
    • In one study in Italy in 1946, 21 contacts who received vaccine within 5 days after exposure and in whom smallpox subsequently developed all had mild disease, whereas 31 contacts who were vaccinated 6 to 10 days after exposure had a case-fatality rate of 19% (see References: Dixon 1948). These findings suggest a protective effect for postexposure vaccination only if vaccine is administered within several days after exposure.
    • In another study involving 34 patients vaccinated during the incubation period, nine were vaccinated at least 8 days before illness onset; four (44%) of these patients died. Twenty-five were vaccinated 7 or fewer days before illness onset; 10 (40%) of these patients died (see References: Guha Mazumder 1975).
  • How late after exposure individuals can be vaccinated and not become ill is unclear.

Use of Vaccine During a Smallpox Emergency

During the smallpox eradication campaign and during smallpox outbreaks in the past, a "ring vaccination" strategy has been followed. This approach is incorporated into the current CDC Interim Smallpox Plan (see References: CDC: Interim smallpox response plan and guidelines: Guide B). Ring vaccination essentially involves creating a circle of vaccinated persons around each case to interrupt the chain of transmission. The strategy involves the following steps:

  • Rapid identification and isolation of all smallpox cases
  • Identification and vaccination of contacts of smallpox cases
  • Monitoring contacts for development of fever and isolating them if fever occurs
  • Vaccination of household members of contacts if no contraindications to vaccination exist

In addition to ring vaccination, rapid voluntary vaccination of a large population may be required to:

  • Supplement priority surveillance and containment control strategies in areas with smallpox cases
  • Reduce the "at-risk" population for additional intentional releases of smallpox virus if the probability of such occurrences is considered significant
  • Address heightened public or political concerns regarding access to voluntary vaccination

Large-scale voluntary smallpox vaccination would only be initiated in certain situations under recommendations from the Secretary of Health and Human Services. Wide-scale quarantine of communities likely would not be effective and, therefore, would not be recommended (see References: Barbera 2001).

Guide B of the CDC interim smallpox guidelines provides detailed information on use of smallpox vaccine during an emergency situation (see References). Key points for vaccine use are outlined in the table below.

Vaccination Guidelines for Use of Smallpox Vaccine During a Smallpox Emergency

Who to vaccinate:
-Persons exposed to initial release of the virus if release is discovered during first generation of cases during a time when vaccination would still be of benefit (ie, within 4 days after exposure)
-Persons who have face-to-face, household, or close proximity contact (ie, up to 6.5 ft) with a confirmed or suspected smallpox patient after fever develops in patient and until all scabs have separated
-Personnel selected for direct medical or public health evaluation, care, or transportation of confirmed, probable, or suspected smallpox patients
-Laboratory personnel selected for collection or processing of clinical specimens from confirmed, probable, or suspected smallpox patients
-Other persons with increased likelihood of contact with infectious materials from a smallpox patient (eg, laundry or medical-waste handlers for a facility where smallpox patients are admitted)
-Other groups whose unhindered function is deemed essential to support of response activities and who are not otherwise involved in patient-care activities but who have a reasonable probability of contact with smallpox patients or infectious materials (eg, selected law enforcement, emergency response, or military personnel)
-Because of potential for greater spread of smallpox in a hospital setting due to possible aerosolization of virus from a severely ill patient, consideration should be given to vaccination of all persons present in hospital during time a case was present and not isolated in an appropriate manner(in a room with ventilation separate from other areas of the hospital

Contraindications for vaccination of noncontacts*†:
-Persons with diseases or conditions that cause immunodeficiency
-Persons with serious, life-threatening allergies to the antibiotics polymyxin B, streptomycin, tetracycline, or neomycin
-Persons who have ever been diagnosed with eczema, even if the condition is mild or not active
-Pregnant women
-Persons with other acute or chronic skin conditions such as atopic dermatitis, burns, impetigo, or varicella-zoster (shingles) should not be vaccinated until condition resolves

*Generally, those with vaccine contraindications who have face-to-face contact with a smallpox patient are at greater risk for development of smallpox than for complications from vaccination and should be considered for vaccination.
†Persons who have contraindications to vaccination and who are household members of contacts who receive vaccine should consider housing themselves separately from vaccinated household members until vaccination site has healed. This will decrease risk of contact transmission through vaccination site.
Adapted from CDC: Interim smallpox response plan and guidelines: Guide B (see References).

On September 23, 2002, CDC released the Smallpox Vaccination Clinic Guide, which is Annex 3 of the Interim Smallpox Guidelines (see References: CDC: Interim smallpox response plan and guidelines: Annex 3). This Guide includes the following information:

  • Vaccine delivery and packaging logistics, including distribution of 280 million doses of smallpox vaccine from the National Pharmaceutical Stockpile
  • Organization of a large-scale vaccination clinic (ie, to vaccinate up to 1 million persons over 10 days)
  • Logistics for IND administration of smallpox vaccine
  • Question and answer sheets on smallpox vaccine for the general public
  • Considerations for mass patient care

Back to top

Infection Control

Isolation Precautions

Airborne and Contact Precautions in addition to Standard Precautions should be implemented for patients with suspected smallpox.

Airborne Precautions:

  • Place the patient in a private room with negative air-pressure ventilation (minimum 6 air exchanges/hr).
  • Use external air exhaust or high-efficiency particulate air (HEPA) filters if the air is recirculated.
  • Keep the door to the room closed.

Contact Precautions:

  • Place the patient in a private room if available.
  • If a private room is not available, place the patient in a room with a patient who has active infection with the same organism (ie, cohort patients with smallpox).
  • Wear gloves when entering the room, change gloves after having contact with infectious material, remove gloves before leaving the room, and immediately wash hands using an antimicrobial agent.
  • Wear a gown when entering the room if clothing will have significant patient contact; remove the gown before leaving the room.
  • Move and transport the patient for essential purposes only. If transport is necessary, a mask should be placed on the patient.
  • When possible, dedicate the use of noncritical patient-care equipment.

Vaccination of Healthcare Workers

All healthcare workers caring for patients with suspected smallpox should be vaccinated immediately.

Disinfection/Sterilization of Reusable Medical Equipment

Standard disinfection/sterilization methods should be adequate for medical equipment used on smallpox patients (see References: Rutala 1996).

Cleaning and Disinfection of Environmental Surfaces

Standard hospital disinfectants (eg, hypochlorite and quaternary ammonium compounds) are adequate for cleaning surfaces potentially contaminated with the virus (see References: Henderson 1999: Smallpox as a biological weapon).

Laundry and Waste

Guide F of the CDC interim smallpox guidelines (see References) recommends that all laundry and waste should be placed in biohazard bags and autoclaved before being laundered. If this is not possible, potentially contaminated laundry should be incinerated.

The Working Group on Civilian Biodefense recommends that bedding and clothing of smallpox patients should be autoclaved or laundered in hot water to which bleach has been added (see References: Henderson: Smallpox as a biological weapon).

Decontamination

Guide F of the CDC interim smallpox guidelines (see References) states that hospital rooms should be fogged with formaldehyde as part of the terminal cleaning process. The use of formaldehyde vapor for terminal disinfection was widely practiced in the pre-eradication era of smallpox (see References: Grossgebauer 1975).

The practice of fogging generally has been discouraged more recently. Standard terminal cleaning practices should be effective in preventing transmission of the virus (see References: CDC: Smallpox: what every clinician should know.)

Back to top

Public Health Reporting and Case Definitions

A case of smallpox is considered a public health emergency; therefore, any patients with a likely diagnosis of smallpox should be reported immediately to the state or local health department, according to disease reporting rules.

Case definitions are as follows (see References: CDC: Interim smallpox response plan and guidelines: Guide A).

Clinical case definition:

  • An illness with acute-onset fever of 101°F or more followed by a rash characterized by vesicles or firm pustules in the same stage of development without other apparent cause.

Laboratory criteria for confirmation:

  • Isolation of smallpox (variola) virus from a clinical specimen (Level D laboratory) or
  • PCR identification of variola DNA in a clinical specimen or
  • Negative stain electron microscopy identification of variola virus in a clinical specimen (Level D laboratory or approved Level C laboratory)

Case classification:

  • Confirmed: A case of smallpox that is laboratory confirmed
  • Probable: A case that meets the clinical case definition and is not laboratory-confirmed but has an epidemiologic link to another confirmed or probable case
  • Suspected: A case that meets the clinical case definition but is not laboratory-confirmed and does not have an epidemiologic link to a confirmed or probable case of smallpox, or a case that has an atypical presentation and is not laboratory-confirmed but has an epidemiologic link to a confirmed or probable case of smallpox

Back to top

References

Aldea C, Alvarez CP, Folgueira L, et al. Rapid detection of herpes simplex virus DNA in genital ulcers by real-time PCR using SYBR green I dye as the detection signal. J Clin Microbiol 2002;40(3):1060-2 [Full text]

Alibek K. Biohazard. New York, NY: Random House, 1999

Arita I, Jezek Z, Khodakevich L, et al. Human monkeypox: a newly emerged othropoxvirus zoonosis in the tropical rain forests of Africa. Am J Trop Med Hyg 1985 Jul;34(4):781-9

Arnt N, Morris L. Smallpox outbreaks in two Brazilian villages: epidemiologic characteristics. Am J Epidemiol 1972;95(4):363-70

Barbera J, Macintyre A, Gostin L, et al. Large-scale quarantine following biological terrorism in the United States: scientific examination, logistic and legal limits, and possible consequences. JAMA 2001;286(21):2711-7 [Full text]

Bezold GD, Lange ME, Gall H, et al. Detection of cutaneous varicella zoster virus infections by immunofluorescence versus PCR. Eur J Dermatol 2001; 11(2):108-11 [Abstract]

Bicknell WJ. The case for voluntary smallpox vaccination. N Engl J Med 2002;346(17):1323-5 [Full text]

Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346(17):1300-8 [Full text]

Breman JG, Kalisa-Ruti, Steniowski MV, et al. Human monkeypox, 1970-79. Bull WHO 1980;58(2):165-82

CDC. Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC strategic planning workgroup. MMWR 2000:49(RR04):1-14 [Full text]

CDC: Biosafety in microbiological and biomedical laboratories (BMBL). Ed 4, April 1999 [Full text]

CDC. Drug Service [Web page]

CDC. Emergency response [Web page]

CDC. Generalized vesicular or pustular rash illness protocol [Web page]

CDC. Human monkeypox-Kasai Oriental, Zaire, 1996-1997. MMWR 1997;46(14):304-7 [Full text]

CDC. Interim smallpox response plan and guidelines, Jan 23, 2002
Index
Annex 3-Smallpox vaccination clinic guide
Guide A-Surveillance, contact tracing, and epidemiological investigation
Guide B [pp 1-12] [pp 13-19]-Vaccination guidelines for state and local health departments
Guide D-Specimen collection guidelines
Guide F-Decontamination guidelines

CDC. Laboratory associated smallpox-England. MMWR 1978;27:319-20

CDC. Smallpox: what every clinician should know (Webcast, Dec 13, 2001)

CDC. Smallpox: rash illness images [Web page]

CDC. Smallpox surveillance-worldwide. MMWR 1977;46(42):990-4 [Full text]

CDC. Supplemental recommendations of the ACIP: use of smallpox (vaccinia) vaccine, June 2002 [Full text]

CDC. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR 2001;50(RR10):1-25 [Full text]

CDC. Smallpox: vaccine reaction images [Web page]

Chan EL, Brandt K, Horsman GB. Comparison of Chemicon SimulFluor direct fluorescent antibody staining with cell culture and shell vial direct immunoperoxidase staining for detection of herpes simplex virus and with cytospin direct immunofluorescence staining for detection of varicella-zoster virus. Clin Diagn Lab Immunol 2001; 8(5):909-12 [Full text]

Chemicon, Inc. Home page [http://www.chemicon.com]

Cohen PR. Tests for detecting herpes simplex virus and varicella-zoster virus infections. Dermatol Clin 1994; 12(1):51-68 [Abstract]

Dixon CW. Smallpox. London, England: J & A Churchill Ltd, 1962

Dixon CW. Smallpox in Tripolitania, 1946: an epidemiological and clinical study of 500 case, including trials of penicillin treatment. J Hygiene 1948;46(4):351-77

Downie AW, Fedson DS, Saint Vincent L, et al. Haemorrhagic smallpox. J Hyg 1969;67(4):619-29

Espy MJ, Teo R, Ross TK, et al. Diagnosis of varicella-zoster virus infections in the clinical laboratory by LightCycler PCR. J Clin Microbiol 2000;38(9):3187-9 [Full text]

Fauci AS. Smallpox vaccination policy-the need for dialogue. N Engl J Med 2002;346(17):1319-20 [Full text]

Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva, Switzerland: World Health Organization, 1988 [Full text]

Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278(5):399-411 [Abstract]

Frey SE, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346(17):1265-74 [Full text]

Frey SE, Newman FK, Cruz J, et al. Dose-related effects of smallpox vaccine N Engl J Med 2002;346(17):1275-80 [Full text]

Gani R, Leach S. Transmission potential of smallpox in contemporary populations. Nature 2001;414:748-51 [Abstract-requires free registration]

Gerson AA, LaRussa P, Steinberg SP. Varicella-zoster virus. In: Murray PR, Baron EJ, Pfaller MA, et al, eds. Manual of clinical microbiology. Ed 7. American Society for Microbiology Press; Washington, DC, 1999

Gilchrist MJR. The progress, priorities and concerns of public health laboratories. Presented at the Forum on Infections, Biological Threats and Terrorism, Institute of Medicine, Nov 28, 2001 [Full text]

Grossgebauer K, Spicher G, Peters J, et al. Experiments on terminal disinfection by formaldehyde vapor in the case of smallpox. J Clin Microbiol 1975;2(6):516-9

Guha Mazumder DN, De S, Mitra AC, et al. Clinical observations on smallpox: a study of 1,233 patients admitted to the infectious diseases hospital, Calcutta, during 1973. Bull WHO 1975;52:301-6

Hawrami K, Breuer J. Development of a fluorogenic polymerase chain reaction assay (TaqMan) for the detection and quantitation of varicella zoster virus. J Virol Methods 1999;79(1):33-40 [Abstract]

Heiner GG, Fatima N, McCrumb FR. A study of intrafamilial transmission of smallpox. Am J Epidemiol 1971;94(4):316-26

Henderson DA. Bioterrorism as a public health threat. Emerg Infect Dis 1998;4(3):488-92 [Full text]

Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. JAMA 1999;281(22):2127-39 [Full text]

Henderson DA, Fenner F. Recent events and observations pertaining to smallpox virus destruction in 2002. Clin Infect Dis 2001;33(7):1057-9 [Full text]

Henderson DA. Smallpox: clinical and epidemiologic features. Emerg Infect Dis 1999;5(4):537-9 [Full text]

Jain S, Wyatt D, McCaughey C, et al. Nested multiplex polymerase chain reaction for the diagnosis of cutaneous herpes simplex and herpes zoster infections and a comparison with electronmicroscopy. J Med Virol 2001;63(1):52-6 [Abstract]

Jezek Z, Grab B, Szczeniowski MV, et al. Human monkeypox: secondary attack rates. Bull WHO 1988;66(4):465-70

Jezek Z, Marennikova SS, Mutumbo M, et al. Human monkeypox: a study of 2,510 contacts of 214 patients. J Infect Dis 1986;154(4):551-5 [Abstract]

Jezek Z, Szczeniowski M, Paluku KM,et al. Human monkeypox: clinical features of 282 patients. J Infect Dis 1987;156(2):293-8 [Abstract]

Johns Hopkins Center for Civilian Biodefense Studies. Smallpox virus destruction [Web page]

Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002;5(2):84-6 [Full text]

Ker FL. Variola minor: observations and experiences in Staffordshire, England, during 1966. Clin Pediatr 1967;6(9):533-9

Khodakevich L, Aezek Z, Messinger D. Monkeypox virus: ecology and public health significance. Bull WHO 1988;66(6):747-52

Kitamura T, Aoyama Y, Kurata T, et al. Virological studies of smallpox in an endemic area. II. Virus content of clinical specimens and typing of virus isolates. Jpn J Med Sci Biol 1977; 30(5):229-39

Koenig M, Reynolds KS, Aldous W, et al. Comparison of Light-Cycler PCR, enzyme immunoassay, and tissue culture for detection of herpes simplex virus. Diagn Microbiol Infect Dis 2001;40(3):107-10 [Abstract]

Koplan JP, Foster SO. Smallpox: clinical types, causes of death, and treatment. J Infect Dis 1979;140(3):440-1

Lane JM, Ruben FL, Neff JM, et al. Complications of smallpox vaccination,1968: results of 10 statewide surveys. J Infect Dis 1970;122:303-9

Lapa S, Mikheev M, Shchelkunov S, et al. Species-level identification of orthopoxviruses with an oligonucleotide microchip. J Clin Microbiol 2002;40(3):753-7 http://jcm.asm.org/cgi/content/full/40/3/753?view=full&pmid=11880388

LeDuc JW, Becher J. Current status of smallpox vaccine. (Letter) Emerg Infect Dis 1999;5(4):593-4 http://www.cdc.gov/ncidod/eid/vol5no4/letters.htm

LeDuc JW, Jahrling PB. Strenthening national preparedness for smallpox; an update. Emerg Infect Dis 2001;7(1):155-7 http://www.cdc.gov/ncidod/eid/vol7no1/leduc.htm

Marennikiva SS, Gurvich EB, Yumasheva MA. Laboratory diagnosis of smallpox and similar viral diseases by means of tissue culture methods. Acta Virol 1974;8:135-42

Marsden JP. Variola minor: a personal analysis of 13,686 cases. Bull Hyg 1948;23:735-46

Nicoll S, Brass A, Cubie HA. Detection of herpes viruses in clinical samples using real-time PCR. J Virol Methods 2001 96(1):25-31[Abstract]

Mehta BC, Doctor RG, Purandare NM, et al. Hemorrhagic smallpox. A study of 22 cases to determine the cause of bleeding. Indian J Med Sci 1967;21(8):518-23

Mitra M, Bhattacharya DK. Some observations on haemorrhagic smallpox (Type I). J Indian Med Assoc 1976;67(11):237-40

Nahass GT, Mandel MJ, Cook S, et al. Detection of herpes simplex and varicella-zoster infection from cutaneous lesions in different clinical stages with the polymerase chain reaction. J Am Acad Dermatol 1995;32(5 Pt 1):730-3 [Abstract]

National Center for Biotechnology Information, National Institutes of Health. GenBank [Web site]

NIAID (National Institute of Allergy and Infectious Diseases). Study seeks to determine effectiveness of diluted smallpox vaccine. Press release, Oct 2001 [Full text]

Oranje AP, Folkers E, Choufoer-Habova J, et al. Diagnostic value of Tzanck smear in herpetic and non-herpetic vesicular and bullous skin disorders in pediatric practice. Acta Derm Venereol 1986;66(2):127-33 [Abstract]

O'Toole T, Mair M, Inglesby TV. Shining light on "Dark Winter." Clin Infect Dis 2002;34:972-83 [Full text]

Rao AR. Smallpox. Bombay, India: Kothari Book Depot, 1972

Rao AR, Jacob ES, Kamalakshi S, et al. Epidemiological studies in smallpox: a study of intrafamilial transmission in a series of 254 infected families. Indian J Med Res 1968;56:1826-54

Ropp SL, Jin Q, Knight JC, Massung RF, Esposito JJ. PCR strategy for identification and differentiation of small pox and other orthopoxviruses. J Clin Microbiol 1995; 33(8):2069-76 [Abstract]

Rutala WA. APIC guideline for selection and use of disinfectants. Am J Infect Control 1996;24:313-42

Ryncarz AJ, Goddard J, Wald A, Huang ML, Roizman B, Corey L. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol 1999;37(6):1941-7 [Abstract]

Sarkar JK, Chatteriee SN, Mitra AC, et al. Antibody response in haemorrhagic smallpox. Indian J Med Res 1967;55(11):1143-9

Sheth SC, Maruthi V, Tibrewala NS, et al. Smallpox in children. Indian J Pediatr 1971;38:129-31

Stearn EW, Stearn AE. The effect of smallpox on the destiny of the Amerindian. Boston, Mass: Bruce Humphries, 1945

Tucker JB, Zilinskas RA. CNS Occasional Paper No 9: The 1971 smallpox epidemic in Aralsk, Kazakhstan, and the Soviet biological warfare program. June 2002 [Full text]

Wehrle PF, Posch J, Richter KH, et al. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull WHO 1970;43(5):669-79

WHO. Smallpox eradication: destruction of variola virus stocks. Executive Board Documentation, Dec 20, 2001 [Full text]

WHO. Fact sheet on smallpox [Web page]

WHO. Smallpox: rash illness slideset [Web page]

Wolff HL, Croon JJAB. The survival of smallpox virus (variola major) in natural circumstances. Bull WHO 1968;38:492-3

Back to top

   

In This Section

Smallpox Web Resources

Smallpox Clinical
Pathways
PDF


Also See

Bioterrorism Homepage

Links to Other Bioterrorism Resources

IDSA Homepage

IDSA Website Policies and Disclaimer



 

Home |  Members Only 
Education &Research |  Meetings & Events |   Journals & Publications 
  Policy & Advocacy |  Professional Development |  Practice Guidelines  
  Membership Information  |  Sitemap |  Search
 
 
©Copyright IDSA/CIDRAP 2002
  Infectious Diseases Society of America    66 Canal Center Plaza, Suite 600    Alexandria, VA 22314
Phone: (703) 299-0200       Fax: (703) 299-0204       
Email: info@idsociety.org  

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.